Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms (vol 13, 1223282, 2023)
FRONTIERS IN ONCOLOGY（2024）
Key words
renal cell carcinoma,lenvatinib,pembrolizumab,sunitinib,bone metastases,liver metastases,lung metastases,sarcomatoid histology
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined